obtained at baseline and weeks 26, 52, and 104. Antibodies to GAD65 were detected using radioimmunoassay (Oslo University Hospital in-house assay using translation-labeled GAD); an antibody index of $0.05 was considered positive and provided a sensitivity of 82% and specificity of 99% (Diabetes Autoantibody Standardization Program 2010).
Plasma samples from 1,505, 862, 436, and 327 patients were tested for GAD, islet cell cytoplasm, IA-2A, and IAA, respectively, and 118 (7.8%) were identified as having LADA. GAD65 was the most prevalent autoantibody (99 patients, 6.5%). At baseline, GAD65-positive linagliptin patients with C-peptide measurements at weeks 28, 52, and 104 compared with glimepiride-treated patients were slightly younger (mean age 59-62 vs. 63-68 years) with lower C-peptide levels (821-944 vs. 1,326-1,425 pmol/L), whereas HbA 1c levels were similar (Table 1 ).
In GAD65-positive patients, fasting C-peptide levels increased from baseline at weeks 28, 52, and 104 in patients treated with linagliptin but decreased in glimepiride-treated patients; betweengroup differences were significant at weeks 28 and 52 (Table 1) . Mean HbA 1c decreased to a similar extent with glimepiride and linagliptin.
This exploratory analysis suggests that over a 2-year disease trajectory in LADA patients, treatment with linagliptin may, at least, have attenuated the rate of decline in C-peptide levels. The lack of a greater HbA 1c reduction with linagliptin suggests that reducing glucotoxicity was not responsible for the observations. Mechanisms that could explain a potential attenuation of decline in C-peptide levels with linagliptin include a b-cell-protective effect through elevation of endogenous glucagon-like peptide 1 (GLP-1) (4), and/or non-GLP-1-related mechanisms through modulation of peptides involved in cell signaling and autoimmunological pathways (5).
The current study, although limited by its exploratory nature, between-group difference in baseline C-peptide levels, lack of information on C-peptide after drug washout, small sample size, and lack of inert comparator, adds to the currently sparse evidence on the effects of oral glucose-lowering drugs in LADA patients (2) . Potential further long-term clinical benefits of linagliptin in LADA patients will be further examined in a substudy of the ongoing CAROLINA trial (NCT01243424). patients and staff who participated in this study. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Giles Brooke (Envision Scientific Solutions, Horsham, U.K.) during the preparation of the manuscript.
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